Company: VRCA
Filing Date: 2025-12-15
Form Type: S-3
Source: 0001193125-25-319225
Chunk: 16

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-15
Form: S-3
Chunk 16
---
 Private Placement and (b) 11,788 shares of our common stock issuable upon exercise of Common Warrants issued to Parallax in the Private Placement. The address of Parallax is c/o 
 Vista Point Capital, P.O. Box 357, Walnut Creek, California 94597.                                                                                                                                                                          |

Relationship with Selling Stockholders Each of the selling stockholders has not had any material relationship with the registrant or any of its predecessors or affiliates, within the past three years, except as described below. As discussed in greater detail above under the section titled “Prospectus Summary—Private Placement,” in November 2025, we entered into the Purchase Agreements with the selling stockholders, pursuant to which we sold and issued shares of our common stock, Pre-FundedWarrants and Common Warrants to purchase our common stock. The Purchase Agreements include certain registration rights, pursuant to which we agreed to prepare and file, within 30 days of closing, one or more registration statements with the SEC to register for resale the Resale Shares. As described below, the selling stockholders include several of our officers and directors, or affiliates thereof, and 5% or greater stockholders. Paul B. Manning is a beneficial owner of more than 5% of our common stock and has served as chairman of our board of directors since 2017. Jayson Rieger has served as our President and Chief Executive Officer and as a director since November 2024. 10

David Zawitz has served as our Chief Operating Officer since December 2024.

John Kirby has served as our Interim Chief Financial Officer since November 2024.

Noah Rosenberg has served as our Chief Medical Officer since March 2025.

Caligan Partners LP is, and prior to the Private Placement was, a beneficial owner of more than 5% of our common stock and, pursuant to the
terms of the Private Placement, has the right to appoint a director as a Class I member of our board of directors for so long as it continues to hold at least half of the Pre-Funded Warrants and/or the Pre-Funded Warrant Shares it purchased in the Private Placement, subject to compliance with Nasdaq listing rules. In addition, so long as Caligan has the right to appoint a member to our board of directors, Caligan
also has the right to designate an observer to our board of directors.

11

PLAN OF DISTRIBUTION The selling stockholders, which as used herein includes donees, pledgees, transfere